Advertisement

Annals of Surgical Oncology

, Volume 24, Issue 11, pp 3338–3344 | Cite as

Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma

  • Brian Badgwell
  • Mariela Blum
  • Prajnan Das
  • Jeannelyn Estrella
  • Xuemei Wang
  • Linus Ho
  • Keith Fournier
  • Richard Royal
  • Paul Mansfield
  • Jaffer Ajani
Gastrointestinal Oncology

Abstract

Purpose

The aim of this phase II study was to perform neoadjuvant hyperthermic intraperitoneal chemoperfusion (HIPEC) via a minimally invasive approach without cytoreduction for patients with gastric cancer and positive peritoneal cytology or low-volume peritoneal carcinomatosis.

Methods

Patients with gastric or gastroesophageal adenocarcinoma and positive peritoneal cytology or radiologically occult peritoneal carcinomatosis after systemic chemotherapy received laparoscopic HIPEC with mitomycin C 30 mg and cisplatin 200 mg. Patients whose peritoneal disease resolved were offered gastrectomy. The primary endpoint was overall survival (OS), with secondary endpoints of HIPEC complications and gastrectomy rate.

Results

We enrolled 19 patients (6 with positive peritoneal cytology only and 13 with peritoneal carcinomatosis) and treated them with 38 laparoscopic HIPEC procedures. Patients had received a median of 8 cycles (range 3–12) of systemic chemotherapy prior to enrollment. Fourteen patients were also treated with chemoradiotherapy before or between cycles of HIPEC. The complication rate for HIPEC was 11% (4 of 38 procedures), the 30-day mortality rate was 0%, and the median length of hospital stay after HIPEC was 3 days (range 2–6). Five patients went on to receive gastrectomy. The median follow-up was 18.9 months, the median OS from the date of diagnosis of metastatic disease was 30.2 months, and the median OS from the first laparoscopic HIPEC was 20.3 months.

Conclusions

Laparoscopic HIPEC was well tolerated, and an encouraging number of patients demonstrated an absence of peritoneal disease after HIPEC and were able to undergo gastrectomy. Comparative studies will be required to clarify survival benefits.

Notes

Acknowledgements

The authors thank Melissa Burkett of the Department of Scientific Publications for editorial assistance.

Disclosures

Brian Badgwell, Mariela Blum, Prajnan Das, Jeannelyn Estrella, Xuemei Wang, Linus Ho, Keith Fournier, Richard Royal, Paul Mansfield, and Jaffer Ajani have no conflicts of interest to declare.

References

  1. 1.
    World Health Organization, International Agency for Research on Cancer, GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide. http://globocan.iarc.fr. Accessed 6 Mar 2017.
  2. 2.
    Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMedGoogle Scholar
  3. 3.
    National Comprehensive Cancer Network Guidelines Version 1.2017, Gastric Cancer. www.nccn.org. Accessed 1 May 2017.
  4. 4.
    Badgwell B, Cormier JN, Krishnan S, et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol. 2008;15(10):2684–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol. 2010;17(12):3173–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Shiozaki H, Elimova E, Slack RS, et al. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol. 2016;113(1):29–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Badgwell B, Roy-Chowdhuri S, Chiang YJ, et al. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015;111(7):875–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol. 2016;42(8):1123–31.CrossRefPubMedGoogle Scholar
  9. 9.
    Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Magge D, Zenati M, Mavanur A, et al. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol. 2014;21(5):1448–55.CrossRefPubMedGoogle Scholar
  12. 12.
    Facchiano E, Risio D, Kianmanesh R, et al. Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. Ann Surg Oncol. 2012;19(9):2946–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Leake PA, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S27–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Badgwell B, Blum M, Das P, et al. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2017. doi: 10.1007/s00464-017-5668-9.PubMedGoogle Scholar
  15. 15.
    Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.CrossRefPubMedGoogle Scholar
  16. 16.
    Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials. 2005;2(6):467–78.CrossRefPubMedGoogle Scholar
  17. 17.
    Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med. 1995;14(4):357–79.CrossRefPubMedGoogle Scholar
  18. 18.
    Kaplan EM, P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRefGoogle Scholar
  19. 19.
    Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment. Expert Opin Pharmacother. 2014;15(5):623–36.CrossRefPubMedGoogle Scholar
  20. 20.
    Ikoma N, Chen HC, Wang X, et al. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24(9):2679–87.CrossRefPubMedGoogle Scholar
  21. 21.
    Ikoma N, Blum M, Chiang YJ, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23(13):4332–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12:526.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12–26.CrossRefPubMedGoogle Scholar
  24. 24.
    Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Badgwell B. Multimodality therapy of localized gastric adenocarcinoma. J Natl Compr Canc Netw. 2016;14(10):1321–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011;104(6):692–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014;110(3):275–84.CrossRefPubMedGoogle Scholar
  28. 28.
    MD Anderson Cancer Center. Study of cytoreduction, gastrectomy, & hyperthermic intraperitoneal chemoperfusion (HIPEC) in gastric adenocarcinoma and carcinomatosis or positive cytology. https://clinicaltrials.gov/ct2/show/NCT02891447. Accessed 7 Mar 2017.
  29. 29.
    Badgwell B, Blum M, Estrella J, et al. Predictors of survival in patients with resectable gastric cancer treated with preoperative chemoradiation therapy and gastrectomy. J Am Coll Surg. 2015;221(1):83–90.CrossRefPubMedGoogle Scholar
  30. 30.
    van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366(22):2074–84.CrossRefPubMedGoogle Scholar
  31. 31.
    Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017;24(8):2252–8.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Brian Badgwell
    • 1
  • Mariela Blum
    • 2
  • Prajnan Das
    • 3
  • Jeannelyn Estrella
    • 4
  • Xuemei Wang
    • 5
  • Linus Ho
    • 2
  • Keith Fournier
    • 1
  • Richard Royal
    • 1
  • Paul Mansfield
    • 1
  • Jaffer Ajani
    • 2
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Gastrointestinal Medical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Radiation OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  4. 4.Department of PathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  5. 5.Department of BiostatisticsThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations